Pan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics.
Citations
Altmetric
Author
Erlichster, M; Chana, G; Zantomio, D; Goudey, B; Skafidas, EDate
2020-07-20Source Title
Clinical Infectious DiseasesPublisher
Oxford University Press (OUP)Affiliation
Electrical and Electronic EngineeringMedicine and Radiology
Metadata
Show full item recordDocument Type
Journal ArticleCitations
Erlichster, M., Chana, G., Zantomio, D., Goudey, B. & Skafidas, E. (2020). Pan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics.. Clinical Infectious Diseases, https://doi.org/10.1093/cid/ciaa1028.Access Status
Access this item via the Open Access locationOpen Access URL
https://europepmc.org/articles/PMC7454384?pdf=renderOpen Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454384Abstract
BACKGROUND: COVID-19 has highlighted deficiencies in the testing capacity of many developed countries during the early stages of pandemics. Here we describe a strategy utilizing pan-family viral assays to improve early accessibility of large-scale nucleic acid testing. METHODS: Coronaviruses and SARS-CoV-2 were used as a case-study for assessing utility of pan-family viral assays during the early stages of a novel pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for a novel pathogen was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to 60 reference coronaviruses, including SARS-CoV-2. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high-quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression. RESULTS: Due to common HCoV species, a Pan-CoV assay would return false positives for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease. Half of reported Pan-CoV assays identify SARS-CoV-2 and with small adjustments can accommodate diverse variation observed in animal coronaviruses. The target region of one well established Pan-CoV assay is highly resistant to mutation compared to species-specific SARS-CoV-2 RT-PCR assays. CONCLUSIONS: Despite cross-reactivity with common pathogens, pan-family assays may greatly assist management of emerging pandemics through prioritization of high-resolution testing or isolation measures. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation. A strategic stockpile of pan-family assays may improve containment of novel diseases prior to the availability of species-specific assays.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References